Adamas Pharmaceuticals Inc (ADMS) : Bow Street has sold out all of its stake in Adamas Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 151,870 shares of Adamas Pharmaceuticals Inc which is valued at $2,050,245.
Other Hedge Funds, Including , Jane Street Group added ADMS to its portfolio by purchasing 12,186 company shares during the most recent quarter which is valued at $164,511.Rhumbline Advisers reduced its stake in ADMS by selling 394 shares or 2.18% in the most recent quarter. The Hedge Fund company now holds 17,693 shares of ADMS which is valued at $238,856.Alliancebernstein reduced its stake in ADMS by selling 8,093 shares or 1.23% in the most recent quarter. The Hedge Fund company now holds 651,667 shares of ADMS which is valued at $8,797,505. Adamas Pharmaceuticals Inc makes up approx 0.01% of Alliancebernstein’s portfolio.Cheyne Capital Management (uk) Llp boosted its stake in ADMS in the latest quarter, The investment management firm added 60,000 additional shares and now holds a total of 114,765 shares of Adamas Pharmaceuticals Inc which is valued at $1,675,569. Adamas Pharmaceuticals Inc makes up approx 1.47% of Cheyne Capital Management (uk) Llp’s portfolio.
Adamas Pharmaceuticals Inc opened for trading at $13.74 and hit $15.12 on the upside on Thursday, eventually ending the session at $15.07, with a gain of 10.24% or 1.4 points. The heightened volatility saw the trading volume jump to 4,41,260 shares. Company has a market cap of $330 M.
Many Wall Street Analysts have commented on Adamas Pharmaceuticals Inc. Noble Financial Initiated Adamas Pharmaceuticals Inc on Jun 17, 2016 to “Buy”, Price Target of the shares are set at $25.Mizuho Upgraded Adamas Pharmaceuticals Inc on Jun 16, 2016 to ” Buy”, Price Target of the shares are set at $22.
Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.